This study was conducted to examine the ef fect of the intramuscular injection of levallorphan tartrate (1.0 mg), a mixed agonist-antagonist opiate, on the neu rological signs, symptoms, and vital signs in 19 patients with acute ischemic stroke. A temporary improvement of hemiplegia or hemiparesis was observed within several minutes after levallorphan injection in 13 of the patients. There were no significant alterations in blood pressure or
first reported that an opiate antagonist, naloxone, reversed the isch emic neurological deficits in patients with cerebral ischemia and suggested that the endogenous opioids play some role in cembral ischemia. Recently, Furui et a!. (1984) reported the increase of �-endorphin level in cerebrospinal fluid in patients with cerebral infarction. These reports suggested the possibility that the endogenous opioids accentuate the delete rious effects of ischemic events. It is therefore im portant to observe the effects of opiate antagonists in these ischemic events. There are several types of opiate antagonists. Only naloxone, however, has been applied to stroke patients, and the effects of this antagonist in reversing neurological deficits have been controversial (Fallis et a!., 1984; Perraro et a!., 1984) . Naloxone is said to be a single opiate receptor antagonist, whereas other types of opiate antagonists, such as the mixed agonist-antagonist pulse rate after injection. The findings indicate that lev allorphan may have a temporary improving effect on neu rological deficits in acute ischemic stroke. In addition, observation of the response to levallorphan may serve to predict the prognosis of the final neurological outcome in this type of patient. Key Words: Cerebral infarction Endogenous opioid-Levallorphan-Opioid antago nist-Opioid receptor.
opiate, are said to act with several types of opioid receptors (Zukin and Zukin, 1981) . Therefore, we attempted to examine the effect of levallorphan tar trate (Lorfan; Ta keda Chemical Inds. Ltd.), which is known to be a potent opiate antagonist (one of the mixed agonist-antagonist opiates), in acute stroke. In this preliminary study, the neurological signs and symptoms after levallorphan administra tion were evaluated and the final neurological out comes compared. On the basis of these results, a temporary improvement of neurological signs was found, and interesting observations were obtained suggesting that the final neurological outcome could be predicted.
PATIENTS AND METHODS
Nineteen patients (38-80 years old, 15 men and 4 women) with acute ischemic stroke were studied. They were admitted to our division of the Osaka University Medical School Hospital sequentially from December 1983 to April 1984. Informed consent was obtained from each subject prior to the initiation of the study in accor dance with the Helsinki Declaration of 1975. Patients with transient ischemic attack and cerebral hemorrhage were excluded by neurological examinations, computed to mography (CT), and angiography. CT was performed at least two times in all cases (on admission and at 1-2 weeks after the first examination). The size of the low density area in the CT findings was classified as follows: (a) large, occupying more than one-half of the affected hemisphere in a single CT slice (one case); (b) moderate. occupying from one-fifth to one-half of the affected hemi sphere (six cases); (c) small, occupying less than one-fifth of the affected hemisphere (five cases); (d) multiple, la cunar stroke (one case); (e) no remarkable findings (six cases). Five of the patients had hemiplegia and 13 had hemiparesis. Two patients (cases 16 and 18) had motor aphasia. Two patients (cases 4 and 10) had superficial sensory disturbance. The consciousness level of the pa tients was clear except for one semicomatous patient (case 15). The case summaries are presented in Ta ble I.
In all patients, 1. 0 mg of levallorphan tartrate was ad ministered one or more times by intramuscular injection. The method of administration was as follows: Levallor phan or saline was randomly selected and administered 4 h apart with both the examiner and the patient blind as to which had been given. The initial treatment was be tween 1 and 10 days after onset (Table 1) .
Motor function disturbances were evaluated by using a modified Mingazzini test for the upper extremities and a modified Barre test for the lower extremities. The Min gazzini test for the upper extremities is a simple method for detecting mild paresis: The patient is ordered to sit and maintain both arms straight forward against gravity and a paretic arm-drop is observed. The Barre test is also employed to detect mild paresis: The patient lies prone, flexes the knee �90°, and is ordered to maintain it flexed against resistance. The modified Mingazzini test and the Barre test have been designed to grade mild paresis ac cording to the following: Grade 1, complete hemiplegia; Grade 2, severe hemiparesis (the Mingazzini and/or the Barre sign is observed without any weight load); Grade 3, moderate hemiparesis (the sign is observed with a 300g load on the hand for the Mingazzini test and on the foot for the Barre test); Grade 4, mild hemiparesis (the Min gazzini and/or the Barre sign is observed with a 500-g load); Grade 5, no disturbance. Sensory disturbance was evaluated mainly by the test for superficial sensation. Aphasia was assessed by the naming test for five items (watch, pencil, handkerchief, lighter, and cigarette).
Improvement of motor function disturbance after med ication was evaluated according to the following criteria: marked improvement ( + + + + ) (the grade of motor dis turbance before the drug administration was changed by a four-step more favorable grade after administration, e. g. , from complete hemiplegia to no disturbance); good improvement ( + + + ) (changed by a three-step more fa vorable grade); moderate improvement (+ +) (changed by a two-step more favorable grade); mild improvement (+) (changed by one more favorable grade); no marked change (-). Improvements of sensory disturbance and aphasia were also evaluated by the changes in findings in the conventional neurological test. Examination of neu rological and vital signs (blood pressure and pulse rate) were repeated at 0, 5, 10, 15, 30, 60,90, and 120 min after drug administration. Neurological findings of all patients were observed until a plateau was reached. The paired t test was used for laboratory data analysis and the un paired t test and Yates corrected X l test (XC 2 test) were used for clinical comparisons.
RESULTS
Motor disturbance was improved temporarily in 13 of the patients after levallorphan administration, whereas no patient responded to the saline injec tion. Superficial sensory disturbance was improved by levallorphan in one (case 10) of two patients.
There was no neurological improvement in patients with aphasia (cases 16 and 18) after levallorphan administration ( Table I) . The reversal effect of lev allorphan on motor disturbance became apparent within several minutes after levallorphan injection.
The effect reached a maximum level most fre quently from 16 to 30 min after injection and dis appeared in 2 or 3 h in all cases. The degrees of maximum improvement of motor disturbance are shown in Ta ble 1. Similar improvements were ob served on the next day in five of eight patients. In case 12, the initial administration of levallorphan was given on the fifth day after onset and the second administration on the sixth day. Although motor disturbance was mildly improved (i.e., from com plete hemiplegia to severe hemiparesis at 30 min after the first injection), the motor disturbance was not changed by levallorphan on the next day. In other patients (cases 14 and 19) given levallorphan two times, the motor disturbance was not changed.
The level of consciousness was not changed by lev allorphan in the one semicomatous patient (case 15). Ta ble 1 shows that the degree of maximum im provement of motor disturbance by levallorphan, although temporary, was quite similar to the final neurological outcome. No significant differences in age and interval from onset were observed between the levallor phan-effective group (cases 1-13) and the ineffec tive group (cases 14-19); i.e., age-effective group 60 ± 3 years, ineffective group 58 ± 3 years; in terval-effective group 2.7 ± 0.1 days, ineffective group 3.3 ± 1.0 days (means ± SEM). From ob servation of the CT findings, 10 of 13 had small low density areas or no apparent abnormalities in the effective group, and in the ineffective group, only one patient had no apparent CT abnormalities and These fractions indicate the proportions of mild computed to mography (CT) findings (�small low-density area) and of mild neurological outcome (�mild hemiparesis) in each group. X c 2 ,
Yates corrected X l value.
" One aphasia patient without apparent motor deficits was omitted.
the others had more severe abnormalities (Tables 1 and 2). From observation of the residual motor def icits of the patients, the levallorphan-effective group was found to have milder motor disturbance finally than the ineffective group (Tables 1 and 2).
These comparisons were statistically significant (p < 0.05 for both) ( Table 2) .
Levallorphan did not alter blood pressure or pulse rate. There were no significant changes in blood chemistry or peripheral blood analysis be tween pre-and postmedication.
DISCUSSION
In the present study, a temporary improvement of neurological deficits was found in 13 of 19 cases after levallorphan administration. There was no im provement in language function in two patients with aphasia and no improvement of consciousness dis turbance. These reversal effects were clearly ob served without stimulation by the examiner. The patients could move the upper and lower extremi ties more smoothly after levallorphan injection.
Since the initial report of Baskin and Hosobuchi (1981) , various studies with endogenous opioids in stroke, both clinical and experimental, have been reported. These reports suggest the possibility that the endogenous opioids play some role in acute stroke. Observation of the effects of opiate antag onists in stroke is therefore important. There are several types of opiate antagonists that are used clinically, but only naloxone has been applied to stroke patients. In addition, the reversal effects of naloxone have been controversial (Bousigue et al., 1982; Fallis et al., 1984; Jabaily and Davis, 1984; Perraro et al., 1984) . Naloxone is said to be a single opiate receptor (f.L) antagonist, whereas other types of opiate antagonists, such as levallorphan, are said to act with several types of opioid receptors (Zukin and Zukin, 1981) . We therefore attempted to ad minister levallorphan in patients with acute stroke.
Although levallorphan is thought to have more po tent neurological reversal effects than naloxone, it would be presumptuous to make a conclusion until a comparative study of naloxone and levallorphan is made.
In the present study, all patients were followed up and their final neurological outcome observed.
The degree of maximum improvement on motor dis turbance by levallorphan was almost equal to that on residual motor deficits. It was found that the levallorphan-effective group had milder residual deficits than the ineffective group, and the CT ab normalities in the former group were also milder than in the latter. These results suggest that the ob servation of the maximum effect of levallorphan on motor deficits may serve to predict the neurological prognosis in acute stroke, and the response to lev allorphan is thought to relate to the affected size of CT abnormalities. It should be noted, however, that other factors that may contribute to its effects, such as the disturbed brain area and the natural time course, must be considered.
The possible effect of an opiate antagonist in stroke has been related to modulation of the endog enous opioid system (Hosobuchi et aI., 1982) . From our observation of the neurological outcome and the maximum effect of levallorphan, endogenous opioids may modulate the neurological (especially J Cereb Blood Flow Me/abol, Vol. 5, No.3, 1985 motor) deficits in the acute stage of stroke, and this modulation may be temporary.
In conclusion, we suggest that the findings in this preliminary report show the possibility of a new therapeutic and diagnostic usage of this type of drug. Further studies with these mixed agonist-an tagonist opiates on stroke should be conducted in a larger population.
